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Time to resolution of morbidity: an endpoint for 
assessing the clinical cure of community-acquired 
pneumonia 
R. DAIFUKU*, H. MOVAHHED”, N. FOTHERINGHAM”, M. B. BEAR* AND S. NELSON? 
“Amgen, Thousand Oaks, California and Louisiana State University Medical Center, New Orleans, 
Louisiana, U.S. A. 
Clinical trials of new therapeutics for community-acquired pneumonia (CAP) have typically used a subjective 
endpoint of clinical response. However, as this endpoint is not quantitative, it is subject to observer bias and 
renders the conduct of multicenter trials difficult. For the purposes of conducting a clinical trial of filgrastim, 
as an adjunct to antibiotics for the treatment of CAP, a set of clinical criteria were developed prospectively to 
determine the time when a clinical cure was achieved, based on respiratory rate, temperature, oxygenation and 
roentgenographic findings, which was termed the time to resolution of morbidity (TRM). The TRM was 
evaluated on the first 100 patients entered in this clinical trial. As no clear reference standard exists, the 
predictive value for the duration of parenteral antibiotics (AB) and the length of hospital stay (LOS) was 
compared with that provided by a widely used classification system for severity of disease, APACHE II. The 
TRM was found to correlate significantly better with AB or LOS than APACHE II (P<O.OOl). Furthermore, 
TRM offers the benefit over the endpoints of LOS and AB of being specifically designed to measure the 
patient’s response to therapy, and, in fact, may aid physicians in determining the duration of parenteral 
antibiotic therapy. Hence, TRM is relevant to the clinician and is a useful tool to ensure uniformity in the 
assessment of the response to a new therapeutic in a multicenter clinical trial. 
Background 
Pneumonia is the sixth most common cause of 
death in the United States, with an age-adjusted 
death rate in 1987 of 13.1 per 100000 (1). 
Community-acquired pneumonia (CAP) is not a 
reportable disease and, hence, its incidence and 
prevalence are not well documented. In recently 
published studies of patients requiring hospitalisation 
for the treatment of CAP, mortality rates have 
ranged from 4 to 22% (2-5). 
The diagnosis of CAP is usually based on the 
presence of a new radiographic pulmonary infiltrate 
and the acute onset of cough, purulent sputum 
production or fever (3). The difficulty in establishing 
a specific diagnosis is due to several factors. Sputum 
samples are often collected or handled poorly, some 
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patients with pneumonia do not expectorate sputum, 
and, finally, it is often difficult to distinguish colonis- 
ation from infection (6). Similarly, the resolution of 
pneumonia has been difficult to define. In recently 
published guidelines for the evaluation of anti- 
infectives for the treatment of respiratory tract 
infections, a ‘clinical cure’ is defined as ‘complete 
resolution of all signs and symptoms of pneumonia 
and improvement or lack of progression of all abnor- 
malities on the chest radiograph’ (7). Hence, for the 
purposes of a clinical trial of filgrastim (recombinant 
methionyl human granulocyte-colony stimulating 
factor) for the treatment of CAP, a set of criteria 
was defined prospectively, based on signs followed 
commonly by physicians, to determine the time of the 
clinical resolution of pneumonia which was termed 
the time to resolution of morbidity (TRM). The 
development of TRM was necessary in part because 
of the concern that the marked neutrophilia induced 
by filgrastim in some non-neutropenic patients could 
lead to observer bias in the assessment of a clinical 
cure. 
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Filgrastim has been shown to improve survival in 
animal models of pneumonia (8,9), and has been 
administered safely in patients with presumed CAP at 
doses of up to 600 pg day - t (10). The utility of TRM 
as a measure of clinical cure was evaluated on the 
first 100 patients randomized in a double-blind, 
placebo controlled trial of filgrastim for the treatment 
of CAP. While TRM was expected to correlate with 
both duration of intravenous antibiotic use (AB) and 
length of hospital stay (LOS), this correlation was 
not anticipated to be perfect because of the varia- 
bility in physician practices in prescribing antibiotics, 
and the influence of concomitant medical illness or 
social factors on hospital discharge. 
Material and Methods 
PATIENTS 
Patients hospitalised for the treatment of CAP 
with intravenous antibiotics were eligible to be 
enrolled in this trial. Patients were randomised to 
receive filgrastim or placebo as early as possible but 
no later than 18 h from the time of admission to the 
hospital. Study drug was administered subcutane- 
ously for a minimum of 3 days to a maximum of 
10 days. Patients were followed for 28 days. When 
patients met TRM, physicians were required to 
discontinue the study drug. 
Inclusion criteria were as follows: (1) presence of a 
new infiltrate on chest radiograph compatible with 
the diagnosis of bacterial pneumonia; (2) either a 
Gram-stain of a sputum specimen obtained from 
the lower respiratory tract compatible with the diag- 
nosis of bacterial pneumonia, i.e. < 10 or <2+/4+ 
squamous epithelial cells per low power field, and 
225 or 2 3+/4+ white blood cells per low power 
field, and bacteria of one predominant pathogenic 
species, or a Gram-stain of pleural fluid with a pre- 
dominant pathogenic species, OY bacteremia with a 
likely respiratory pathogen (e.g. S. pneumoniue or H. 
in&enzae); (3) core temperature 2 38.3”C (100.9”F); 
(4) respiratory rate 224 breaths min ~ ‘; and (5) 
hospitalisation expected to require a minimum of 
72 h of intravenous antibiotic therapy. 
Patients were also required to have two or more of 
the following risk factors for severe disease: (1) age 
265 years; (2) pre-existing chronic illness requiring 
on-going medical therapy; (3) splenectomy or prior 
splenic irradiation; (4) chest radiograph with multi- 
lobar infiltrates; (5) relative leukopenia (leukocyte 
count ~6 x lo9 l- ‘; (6) hypoxemia (PaO,/nO, 
<2X5) or (7) systolic blood pressure 590 mmHg 
responsive to the administration of intravenous fluid 
challenge. 
The following were the major exclusion criteria 
that rendered patients ineligible for the study: (1) 
known AIDS by 1987 Centers for Disease Control 
criteria (11); (2) hypotension requiring vasopressors, 
except for ‘renal doses’ of dopamine, defined as 
<3pgkg-‘min-‘; (3) diagnosis of adult respirat- 
ory distress syndrome (ARDS) as suggested by dif- 
fuse bilateral infiltrates, severe hypoxemia with PaO,l 
FIO, ~200, mechanical ventilation with PEEP 
>5 cm H,O, and no evidence of heart failure; (4) 
radiographic, clinical or laboratory data suggestive 
of atypical pneumonia (Chlamydia spp., Myco- 
plasma spp. and Legionella spp.), Pneumocystis 
cavinii pneumonia, tuberculosis, or post-obstructive 
pneumonia; (5) hematologic abnormality as de- 
termined by platelet count ~75 000 mm- 3, absol- 
ute neutrophil count (ANC) c 1000 mm - 3 or 
>40 000 mm ~ 3, or any hematologic malignancy 
including myelodysplastic syndrome; and (6) treat- 
ment with a parenteral antibiotic or ventilator 
support for 224 h prior to enrollment in this study. 
DERIVATION OF TRM 
The TRM was designed to substitute for the non- 
quantitative clinical judgement of cure (7), a set of 
relatively quantitative signs that are followed com- 
monly in medical practice, thus assuring uniformity 
across centers and reducing possible observer bias. 
The TRM was defined as the number of days 
between the day of randomisation (Day 1) and the 
day when the last of the following parameters is met: 
(1) 
(4 
(3) 
(4) 
Improvement or stability (lack of progression) 
of all abnormalities in the chest radiographs as 
compared with serial films obtained in previous 
days. Worsening was defined as an increase in 
the size or the presence of new radiographic 
opacities. Radiographic opacities included inter- 
stitial or alveolar infiltrates, abscess and para- 
pneumonic effusion. Improvement or stability 
were defined, respectively, as a decrease or no 
change in the size of radiographic abnormalities. 
Median respiratory rates, taken for a full minute 
at rest in a sitting or recumbent position, 
for three consecutive 8-h periods of 524 
breaths min - ’ with no single measurement of 
2 30 breaths min - ‘. 
Oral temperature of <37,9”C over three con- 
secutive 8-h periods; and 
Normalised oxygenation defined as PaOJFIO, 
2285; or 290% 0, saturation on room air; or 
for patients with history of severe hypoxemia 
(PaO,lflO, <285), a return to within 10% of the 
most recent pre-morbid baseline PaO,lfiO,. A 
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patient cannot meet this criterion while on 
mechanical ventilation. 
Patients who die while under study have their 
TRM set at the maximum period of observation (in 
this case 28 days). Patients who are discharged or 
leave the hospital prior to meeting TRM have their 
TRM set at the date of discharge. 
The TRM was originally tested and refined on a 
retrospective data set obtained by chart review of 
61 patients with CAP, meeting the major inclusion 
criteria. Analysis of these data indicated that TRM 
was strongly correlated with length of hospital stay 
(r=0.85) and duration of intravenous antibiotic 
use (r=O.90). 
DATA COLLECTION 
For the purposes of this study, data were extracted 
from patient charts and recorded in study forms. In 
addition to demographic and laboratory data, the 
following data of relevance to the evaluation of TRM 
were collected while the patients were hospitalised: 
(1) vital signs: highest temperature, pulse and I-min 
respiratory rate, and blood pressure with lowest 
systolic for every 8-h period; (2) arterial blood gas 
(ABG) or oximetry every other day until the criterion 
for TRM was met; (3) chest radiograph every other 
day until stability or improvement was demonstrated; 
(4) duration of intravenous antibiotic administration; 
and (5) duration of hospitalisation. All data neces- 
sary for calculation of the APACHE II score were 
collected in the 24-h period prior to randomisation, 
or in the time between presentation to the hospital 
and randomisation, if less than 24 h. 
STATISTICAL ANALYSIS 
The data analysis was blinded as to treatment 
assignment. Evaluation of TRM was performed on 
all patients who were randomised and met the criteria 
for resolution of TRM. Resolution of an individual 
component of TRM was defined as the day of its first 
occurrence of normalisation. With respect to compo- 
nents that required three consecutive 8-h periods of 
normalisation, the calendar day for the final 8-h 
period was used. Correlation analyses were per- 
formed for each component of TRM vs. LOS and 
AB. Several stepwise multiple regressions were 
conducted to assess the relationship of LOS and AB 
with TRM. 
For each stepwise regression, candidate predictor 
variables (independent variables) were offered to the 
stepwise procedure to determine which, if any, best 
predicted the dependent variable of interest, e.g. 
LOS. At the first step, a candidate predictor that 
‘best’ predicted the dependent variable was selected. 
At each subsequent step, the remaining candidate 
variables were examined to determine additional pre- 
dictive information beyond that which was already 
predicted from the candidate variables selected pre- 
viously. If none of the remaining variables provided 
additional predictive information, the selection pro- 
cedure stopped. Criteria for inclusion in the final 
regression model was a P-value 50.05. 
Patients not meeting TRM prior to the end of the 
28-day study period, prior to discharge or prior to 
death, were considered censored and were excluded 
from analyses examining TRM. 
Correlations were performed between the 
APACHE II score, or the Acute Physiologic Score 
(APS) subset of the APACHE II score, and LOS 
or AB. 
Results 
Patients included in this analysis were enrolled at 
23 centers between 30 December 1992 and 30 April 
1993. Demographic and prognostic data are summa- 
rised in Table 1. The median duration of intravenous 
antibiotics was 5 days and the median duration of 
hospitalisation was 6 days for all patients. Four 
patients (4%) died while under study, and 27 patients 
(27%) were admitted to the intensive care unit (ICU), 
with a median length of ICU stay of 4 days. 
Twenty-one patients were censored for TRM as 
follows: (1) discharged prior to meeting TRM oxy- 
genation criterion (13%) (2) remained on mechanical 
ventilation through Day 28 (2%), (3) discharged prior 
to meeting TRM radiographic criterion (l%), (4) 
died prior to meeting TRM (2%), (5) no post- 
randomisation chest roentgenogram taken (2%) 
and (6) withdrew immediately after randomisation 
(1%). 
Whether or not the patients were censored for 
TRM, the baseline sputum and blood cultures grew 
at least one respiratory pathogen in 57% of the 
patients. Among the 79 patients not censored for 
TRM, positive cultures were obtained from sputum 
(32 patients), blood (eight patients) or both sputum 
and blood (five patients). The predominant patho- 
gens isolated from the positive sputa were as follows: 
Streptococcus pneumoniae (51%), Haemophilus inJu- 
enzae (27%), Moraxellacatarrhalis (8%) and other 
pathogens or mixed cultures (14%). The 13 bacter- 
emit patients had blood cultures positive for S. 
pneumoniae and had a mean TRM of 5.5 days 
(n= 14), while patients who grew S. pneztmoniae from 
their sputum only had a mean TRM of 3.2 days 
(n= 13). No patient had an atypical pathogen isolated 
from the baseline specimens. 
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Table I Demographic and prognostic data 
Not 
censored 
(n=79) 
Censored 
for TRM 
(n=21) 
All 
(n= 100) 
Female 
Male 
Patients admitted to ICU 
Median LOS in ICU (range) 
Deaths (on or before Day 28) 
Median age in years (range) 
Median baseline APACHE II score (range) 
Median duration (days) of intravenous antibiotics (range) 
Median duration of hospitalisation, all patients (range) 
Median duration of hospitalisation, patients discharge alive (range) 
31 
48 
19 
4.5 (l-27) 
(n= 16)* 
65 (20f97) 
15 (4-30) 
(n=78)f 
5 (2-28) 
6 (2-27) 
(t-2=79) 
6 (2-24) 
(n=77) 
14 
3.5 (P-7) 
(n=6)* 
2 
71 (29-88) 
16 (6-27) 
(n=21) 
6 (l-28) 
6.5 (3-27) 
(n=18)* 
6 (3-23) 
(n=15)* 
38 
62 
27 
4 (l-27) 
(n=22)* 
67 (20497) 
16 (4-30) 
(n=99) 
5 (l-28) 
6 (2-27) 
(n=97)* 
6 (2-24) 
(n=92)* 
TRM, time to resolution of morbidity; ICU, intensive care unit; LOS, length of hospital stay. 
*Patients censored for length of stay were excluded from these estimates. 
I-One patient withdrew consent prior to administration of study drug. 
Table 2 Time to resolution of morbidity (TRM) compo- (CXR) was most likely to resolve last, followed by 
nents last to resolve oxygenation, respiratory rate and temperature. 
TRM 
component 
Frequency (%) 
n=79 
Temperature 
Unique 
Tied 
Total 
Respiratory rate 
Unique 
Tied 
Total 
CXR 
Unique 
Tied 
Total 
Oxygenation 
Unique 
Tied 
Total 
6 (7.6%) 
18 (22.8%) 
24 (30.4%) 
10 (12.7%) 
13 (16.5%) 
23 (29.1%) 
22 (27.8%) 
22 (27.8%) 
44 (55.7%) 
15 (19.0%) 
10 (12.7%) 
25 (31.6%) 
CXR, chest X-ray; unique, single component that was the 
last to resolve; tied, at least one other component resolved 
on the same day; total, total frequency (unique and tied) of 
the components that were last to resolve. 
To determine whether TRM or its components 
were predictive of LOS, two stepwise regressions 
were conducted. The first regression included the 
TRM components, but excluded the TRM com- 
posite. The second regression included both the TRM 
composite and its components. In the absence of the 
TRM composite, the oxygenation and respiration 
components were independently and significantly 
predictive of LOS, accounting for 50% of the total 
variability. These two components were correlated 
most highly with the TRM composite (u=O.86), and 
were replaced by the TRM composite when this was 
included in the analysis. The latter results suggest 
that, in comparison to any of its components, the 
TRM composite was the single best predictor of 
LOS. The components provided no significant 
additional information beyond TRM itself. The least 
squares equation between TRM and LOS is 
described by LOS (days)= 1.58+1.75(TRM) (~~0.78, 
P<O.OOl) (Fig. 1). 
The median TRM was 3 days (range= l-24 days) 
among the 79 patients who were not censored for 
TRM. Each component was examined for the 
number of times it was the last to resolve and 
therefore determine TRM. Results are presented in 
Table 2. Of the four components, chest radiography 
A similar analysis was conducted for duration of 
intravenous antibiotics. In the absence of the TRM 
composite, the oxygenation and respiration compo- 
nents were independently and significantly predictive 
of duration of intravenous antibiotic use. This result 
closely matches that obtained for LOS. When TRM 
was added to this analysis, it replaced these two 
components, and CXR, the component correlated 
most poorly with TRM, was found to provide 
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Fig. I Regression of length of stay (LOS) on time to 
resolution of morbidity (TRM). n=79, r=0.7805. 
60 
0 
0 10 20 30 
TRM (days) 
Fig. 2 Regression of days of intravenous antibiotic use on 
time to resolution of morbidity (TRM). n=79, r=0.7993. 
additional information (P=O.O48). The relationship 
between duration of intravenous antibiotics (AB) 
and TRM is AB (days)=1.07+1.49(TRM) (u=O%O, 
P~O.001) (Fig. 2). 
Of the four components of TRM, fever alone has 
been proposed as a criterion to determine the length 
of parenteral antibiotic therapy. As suggested above, 
TRM correlates significantly better with the duration 
of parenteral antibiotics than fever (r=0.80 VS. 0.47, 
P<O.OOl), and significantly better with duration of 
hospitalisation (u=O.78 vs. 0.42, P<O.OOl). 
Of the 34 patients with LOS greater than 3 days 
over and above the duration of TRM, 17 patients 
remained in the hospital for a medical work up 
unrelated to pneumonia, 10 patients completed pre- 
scribed courses of parenteral or oral antibiotics, five 
patients awaited placement in nursing homes or other 
facilities, and two patients were evaluated for medical 
conditions that might be related to pneumonia. 
Correlations of the APACHE II score were per- 
formed vs. LOS (r=0.32) and AB (v=O.33). Similar 
analyses were performed for the Acute Physiologic 
Score (APS) of APACHE II vs. LOS (r=0.32) and 
AB (r=0.34). While these correlations were statisti- 
cally significant, TRM correlates significantly better 
with LOS than APACHE II (r=0.78 vs. 0.32, 
P<O.OOl) and APS (r=0.78 vs. 0.32, P<O.OOl), and 
significantly better with AB than does APACHE II 
(~0.80 vs. 0.33, P<O.OOl) or APS (r=0.80 vs. 0.34, 
P<O.OOl). 
Discussion 
The TRM is a composite of medical signs of 
significance in evaluating the response of patients 
with CAP to medical therapy, and offers the benefit 
over other possible endpoints indicating a clinical 
cure, e.g. duration of intravenous antibiotic admin- 
istration or hospital length of stay, in that it is 
determined only by the patient’s response to therapy. 
While there is little data comparing different dura- 
tions of parenteral antibiotic therapy for the treat- 
ment of pneumonia, longer courses may be chosen by 
the treating physician at the time of diagnosis for 
patients with more virulent forms of pneumonia or 
for patients with concomitant bacteremia (12,13). 
Likewise, the length of hospitalisation can be affected 
by factors other than medical, e.g. the patient’s 
functional status or level of home support (12). For 
TRM to have clinical utility as an index of patient 
recovery over and above current endpoints, it had to 
be a good predictor of the length of hospitalisation 
and of duration of parenteral therapy, but not be 
perfectly correlated with these endpoints. The fact 
that TRM was a better predictor of these two out- 
comes than any single component also suggests its 
clinical relevance. For example, it is significantly 
better in this regard than fever alone which, to the 
authors’ knowledge, is the only quantitative criterion 
that has been recommended to determine the length 
of parenteral antibiotic therapy (14). 
Of the 21 patients censored for TRM in this 
analysis, four did not meet TRM by protocol design, 
i.e. two patients who remained on mechanical venti- 
lation throughout the study and two patients who 
died on study. Of the remaining 17 patients, 13 were 
discharged prior to meeting the oxygenation criterion 
and may reflect a shortcoming of the instrument. 
This subset of patients includes eight patients who 
had chronic obstructive pulmonary disease by history 
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and may not have been recognised as hypoxemic at 
their pre-morbid baseline. This inability to document 
pre-morbid hypoxemia in all hypoxemic patients was 
recognised as an issue for the application of TRM 
prior to study initiation. One possibility to decrease 
the number of such censored patients is to lower 
PaO,IfiO, criterion of TRM from 285 to 262, since 
hypoxemia is variously defined as a PaO, of 60 or 
55 mmHg in room air (15). Doing so allows the 
inclusion of five patients who were censored pre- 
viously for TRM, and changes the study day TRM is 
met for only two of 79 patients meeting TRM 
previously. The relationship of TRM to AB or to 
LOS remains virtually unchanged; r=0.70 and 
u=O.73, respectively. The remainder of the analysis 
remains essentially the same except that the model 
predicting the duration of intravenous antibiotics 
from TRM and its components includes TRM alone. 
However, CXR, which was included marginally in 
the original model, is now excluded. 
APACHE II is an ICU-based severity of disease 
classification system that can be used to predict the 
risk of in-hospital death (r=0.56, APACHE II vs. 
risk of in hospital death) (16). The correlation of the 
APACHE II score and APS W. LOS and AB are 
evaluated. The TRM was significantly better corre- 
lated with LOS or AB than either APACHE II or 
APS. The APACHE II score is a composite of the 
APS, the Glasgow coma score and Chronic Health 
Points. Since the APS is a reflection of the physi- 
ologic derangement induced by acute illness, it was 
suspected that it might correlate more closely with 
the outcomes of interest. However, this did not 
turn out to be the case, presumably because the 
length of TRM is influenced primarily by two com- 
ponents: (1) the severity of the pneumonia at admis- 
sion and (2) the effectiveness of medical therapy, 
while the APS or APACHE II score reflects only the 
former. 
Thus, because time to resolution of morbidity or 
TRM is an endpoint that is a composite of four 
clinical signs followed commonly by physicians in 
the treatment of pneumonia, it has relevance to the 
clinician and may aid in the determination of the 
appropriate length of parenteral antibiotic therapy. 
Further, TRM can be used as an endpoint in multi- 
center clinical trials to ensure increased uniformity 
of the assessment of clinical cure in patients with 
CAP. 
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